TargetBeta
TNFSF13B
TNF superfamily member 13b · also BAFF, THANK, BLYS, TALL-1 · CD molecules
2 programs in company-led studies act on TNFSF13B, from 2 companies: 0 in phase 3, 1 approved with new studies. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (2 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| belimumabrule | GlaxoSmithKline | phase 4 | 396 running | – | ChEMBL |
| tibulizumabrule | Eli Lilly | phase 2 | 52 running | IL17A | ChEMBL |
Also acted on by the same programs
Conditions their studies are in
- Arthritis, Rheumatoid, 2 programs
- Scleroderma, Systemic, 2 programs
- Connective Tissue Diseases, 1 program
- Glomerulonephritis, Membranous, 1 program
- Hidradenitis Suppurativa, 1 program
- Lupus Erythematosus, Systemic, 1 program
- Sjogren's Syndrome, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- May 2027tibulizumab · Eli Lilly · phase 2 · NCT06843239
- Jun 29, 2027belimumab · GlaxoSmithKline · phase 4 · NCT06411249
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.